Directions of improving management of innovative activities in pharmaceutical companies




pharmaceutical industry, pharmaceutical enterprise, innovation activity, innovation process, innovation potential, assessment methods, patent strategy, toolkit of patent landscapes


The purpose of the work is to substantiate theoretical provisions and practical recommendations for improving the management of innovative activities of pharmaceutical companies (PC) for the implementation of strategic tasks regarding innovative development and increasing competitiveness.

Materials and methods. To achieve the goal of the study, scientific sources on innovation management and intellectual property management and the peculiarities of the organization of innovation processes in pharmacy were analyzed. When conducting research, methods of information search, systematization, comparison, and generalization were used, as well as the method of expert evaluations, taxonomic analysis, and a graphic method to increase the clarity of the presentation of the material.

The results. The main directions and features of innovative activity in pharmacy have been studied. A generalized algorithm for managing innovative activities in pharmaceutical companies is given. The relevance of evaluating and managing the innovative potential of PC to achieve a synergistic effect from the use of resources involved in innovative activities is substantiated. A structural model of the innovative potential of PC is proposed, which considers the peculiarities of the flow of innovative processes in pharmacy, related to the development and introduction of new pharmaceuticals to the market. A methodical toolkit for quantitative and qualitative evaluation of the innovative potential of PC has been defined. To improve the management of the PC's innovative activity, a methodology for determining the range of management decisions is proposed based on the results obtained in the framework of creating a report on the patent landscape.

Conclusions. In order to achieve the provision of effective and safe domestic drugs to the population of Ukraine, it is necessary to intensify research in the direction of the formation of an effective system of management of the innovative activity of pharmaceutical companies (PC), focused on their gradual transition to an innovative development model. The conducted analysis showed that despite a sufficiently large number of publications devoted to the problems of innovation management, issues related to the problem of forming an effective system of managing the innovative activity of PCs, as well as choosing an effective toolkit for evaluating and managing their innovative potential, taking into account the specifics of the flow of innovative processes in pharmacy, remain insufficiently disclosed and require further research. The proposed structural model of the innovative potential of the FC, a justified methodological toolkit for its assessment, as well as the construction of a cognitive map to determine the most appropriate key components and directions for further improvement and development of the innovative potential will contribute to increasing the efficiency of the innovative activities of enterprises and the implementation of the goals of the innovation strategy. The developed algorithm of preventive management of innovative activity of the PC, aimed at improving the quality of decisions made on innovation management thanks to the use of patent landscape tools, will also contribute to the faster entry into the market of domestically produced innovative medicinal products

Author Biographies

Sanjay Kumar Nayak, Amarox Ukraine LTD

General Director, CEO

Olga Posilkina, National University of Pharmacy

Doctor of Pharmaceutical Sciences, Professor

Department of Management and Quality Assurance in Pharmacy

Olena Litvinova, National University of Pharmacy

Doctor of Pharmaceutical Sciences, Professor

Department of Management and Quality Assurance in Pharmacy


  1. Evaluate Pharma. World Preview 2020, Outlook to 2026. Available at:
  2. Ostashchenko, T., Lutska, A., Tomchuk, V., Koval, A., Solomennyi, A., Snizhynskyi, S. et al. (2023). Current Trends in the Development of the Pharmaceutical Market in Ukraine. Pharmacophore, 14 (4), 64–67.
  3. Kotvitska, A. A., Kutsenko, S. A. (2021). Farmatsevtychna industriia ta naukovi doslidzhennia – skuti odnym lantsiuhom. Apteka online, 29 (1300). Available at:
  4. Işık, E., Orhangazi, Ö. (2022). Profitability and drug discovery. Industrial and Corporate Change, 31 (4), 891–904.
  5. Rennane, S., Baker, L., Mulcahy, A. (2021). Estimating the Cost of Industry Investment in Drug Research and Development: A Review of Methods and Results. INQUIRY: The Journal of Health Care Organization, Provision, and Financing, 58.
  6. Schramm, M. E., Place, K. R., Laskin, A. V. (2022). Framing the strategic R&D paradigm shift in Big Pharma: a content analysis of pharmaceutical annual reports. Journal of Communication Management.
  7. Kermanimojarad, M. (2020). What is the impact of patient recruitment on offshoring of clinical trials? Life Sciences, Society and Policy, 16 (1).
  8. Kinch, M. S., Kraft, Z., Schwartz, T. (2021). 2020 in review: FDA approvals of new medicines. Drug Discovery Today, 26 (12), 2794–2799.
  9. The pharmaceutical industry in figures (2020). EFPIA. Available at:
  10. Laermann-Nguyen, U., Backfisch, M. (2021). Innovation crisis in the pharmaceutical industry? A survey. SN Business & Economics, 1 (12).
  11. Straw, M. (2015). Pharma Must Move Beyond Cooperation to True Collaboration. Available at: Last accessed: 05.04.2024
  12. Moingeon, P., Garbay, C., Dahan, M., Fermont, I., Benmakhlouf, A., Gouyette, A. et al. (2024). L’intelligence artificielle, une révolution dans le développement des médicaments. Médecine/Sciences, 40 (4), 369–376.
  13. Yak vidbuvaietsia tsyfrova transformatsiia biznesu v kompanii «Farmak» – lidera farmatsevtychnoho rynku Ukrainy (2021). Available at: Last accessed: 05.04.2024
  14. Kilkisni metody ekspertnoho otsiniuvannia (2009). Kyiv: NADU, 36.
  15. Aronson, J. K., Green, A. R. (2020). Me‐too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. British Journal of Clinical Pharmacology, 86 (11), 2114–2122.
  16. Shumpeter, Y. A. (2014). Teoriia ekonomichnoho rozvytku. Doslidzhennia prybutkiv, kapitalu, kredytu, vidsotka ta ekonomichnoho tsyklu. Kyiv: Vydavnychyi dim “KyievoMohylianska akademiia”, 246.
  17. Epіfanova, І. Iu., Gladka, D. O. (2022). Methodological approaches to assessing the innovation potential of the enterprise. Innovation and Sustainability, 3, 152–158.
  18. Yepifanova, I., Dzhedzhula, V. (2020). Methodology of evaluation of innovative potential of enterprises. Agricultural and Resource Economics, 6 (3), 171–190.
  19. Stadnyk, V. V., Holovchuk, Yu. O. (2020). Upravlinnia innovatsiiamy na osnovi rozvytku partnerskykh vidnosyn pidpryiemstva. Kamianets-Podilskyi: TOV «Drukarnia «Ruta», 232.
  20. Orlova-Kurylova, O. (2018). The modern methods of evaluation of innovative potential. Visnyk Khmelnytskoho natsionalnoho universytetu, 4, 143–146.
  21. Piatnytska, H. T., Hryhorenko, O. M., Naidiuk, V. S. (2018). Methodical and practical approaches to the evaluation of innovative potential of the catering trade small enterprises. Ahrosvit, 4, 53–59.
  22. Yepifanova I., Dzhedzhula V. Methodology of evaluation of innovative potential of enterprises. Agricultural and Resource Economics. 2020. № 6 (3). С. 171-190.
  23. Dzhedzhula, V., Yepifanova, I. (2020). Components of the innovation potential of industrial enterprises. International Humanitarian University Herald. Economics and Management, 42.
  24. Marchenko, V. M., Tsvirkun, A. S. (2017). The system of management of innovative potential at industrial enterprises. Economic bulletin of NTUU «KPI», 411–417.
  25. Piletska, S., Tkachenko, Y. (2020). Enterprise Innovative Potential in the System of Anti-Crisis Management. Accounting and Finance, 1 (87), 178–184.
  26. Dovbush, V. I. (2022). Innovative potential as a tool for ensuring innovative development of an enterprise. Market Relations Development in Ukraine, 12 (247), 46–51.
  27. Krawczyk-Sokolowska, I., Pierscieniak, A., Caputa, W. (2019). The innovation potential of the enterprise in the context of the economy and the business model. Review of Managerial Science, 15 (1), 103–124.
  28. Klebanova, T. S., Hurianova, L. S., Chahovets, L. O., Panasenko, O. V., Serhiienko, O. A. (2018). Biznes-analityka bahatovymirnykh protsesiv. Kharkiv: Vyd. KhNEU im. S. Kuznetsia, 272.
  29. Posylkina, O. V. (2002). Innovatsiino-investytsiinyi rozvytokfarmatsevtychnoho vyrobnytstva: problemy finansovoho zabespechennia. Kharkiv: Vyd-vo NFAU: Zoloti storinky, 528.
  30. Kryvoruchko, O., Desiatko, A., Karpunin, I., Hnatchenko, D., Lakhno, M., Malikova, F., Turdaliev, A. (2023). Cognitive Modeling and Formation of the Knowledge Base of the Information System for Assessing the Rating of Enterprises. International Journal of Electronics and Telecommunications, 697–705.
  31. Litvinova, O., Klager, E., Tzvetkov, N. T., Kimberger, O., Kletecka-Pulker, M., Willschke, H., Atanasov, A. G. (2022). Digital Pills with Ingestible Sensors: Patent Landscape Analysis. Pharmaceuticals, 15 (8), 1025.
  32. Holgersson, M., Wallin, M. W. (2017). The patent management trichotomy: patenting, publishing, and secrecy. Management Decision, 55 (6), 1087–1099.
Directions of improving management of innovative activities in pharmaceutical companies




How to Cite

Nayak, S. K., Posilkina, O., & Litvinova, O. (2024). Directions of improving management of innovative activities in pharmaceutical companies. ScienceRise: Pharmaceutical Science, (2 (48), 90–102.



Pharmaceutical Science